908258-58-2

Basic information

• Product Name: 3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid
• Synonyms: 3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid;MPEG10-CH2COOH
• CAS NO: 908258-58-2
• Molecular Formula: C₂₃H₄₆O₁₃
• Molecular Weight: 530.6
• Mol File: 908258-58-2.mol

Chemical Properties

• Appearance: /
• Density: 1.122
• CAS DataBase Reference: 3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid(908258-58-2)
• EPA Substance Registry System: 3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid(908258-58-2)

Safety Data

• Hazardous Substances Data: 908258-58-2(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid is used as a linker for bioconjugation, providing a stable and hydrophilic spacer between the target molecule and the functional group. The multiple carboxylic acid groups allow for the attachment of multiple functional groups, enabling the development of multifunctional bioconjugates with enhanced properties.
Used in Drug Delivery Systems:
3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid is used as a building block for the development of drug delivery systems, such as micelles, liposomes, and nanoparticles. The alternating pattern of hydrophilic and hydrophobic regions allows for the encapsulation of hydrophobic drugs, improving their solubility, stability, and bioavailability. The formation of stable amide bonds with primary amine groups enables the covalent attachment of targeting ligands, enhancing the specificity and efficacy of drug delivery systems.
Used in Surface Modification:
3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid is used for surface modification of various materials, such as nanoparticles, polymers, and medical devices. The hydrophilic PEG spacer provides a stable and biocompatible coating, reducing non-specific interactions and improving the overall performance of the modified surfaces. The multiple carboxylic acid groups allow for the attachment of functional groups, enabling the development of multifunctional surfaces with tailored properties.
Used in Cosmetics and Personal Care:
3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanoic acid is used in cosmetics and personal care products as a humectant, emulsifier, and viscosity modifier. The hydrophilic PEG spacer provides a stable and biocompatible coating, improving the texture and feel of the products. The multiple carboxylic acid groups allow for the attachment of functional groups, enabling the development of multifunctional ingredients with enhanced properties.

Upstream product

• 114740-40-8 methoxypolyethylene glycols-S-triphenylmethyl-L-cysteine dopamine 
• 112-60-7 Tetraethylene glycol 
• 23601-40-3 hexaethylene glycol monomethyl ether 
• 27425-92-9 O-methyl-decaethylene glycol 

Relevant articles and documents

Synthesis of non-ionic bolaamphiphiles and study of their self-assembly and transport behaviour for drug delivery applications

A series of four bolaamphiphiles with different hydrophilic units has been synthesised. All the amphiphiles were well characterised from their physiochemical data. The aggregation tendency of newly synthesised amphiphiles was studied using fluorescence spectroscopy, dynamic light scattering (DLS), and cryogenic electron microscopy (cryo-TEM). Furthermore, their application as nanocarriers for hydrophobic guests was demonstrated by using two established standards, i.e. the dye Nile red and the drug nimodipine. A cytotoxicity and cellular uptake study has been carried out using A549 cells. Due to the presence of an ester linkage in PEG based bolaamphiphiles, a drug release study was performed in the presence of an immobilized enzyme Novozym-435 (a lipase).

Monodisperse oligoethylene glycols modified Propofol prodrugs

The low water solubility of Propofol resulted in complicated formulation and adverse effects during its clinical application. To improve its water solubility and maintain its anesthetic effects, Propofol prodrugs with monodisperse oligoethylene glycols as solubility enhancer were designed and synthesized. Monodisperse oligoethylene glycols enable the concise manipulation of water solubility, biocompatibility and anesthetic effects. Through the physicochemical and biological assay, a few water soluble prodrugs of Propofol were identified as promising anesthetic to overcome the drawbacks associated with Propofol.

Preparation and application of monodisperse polyethylene glycol monomethyl ether modified propofol prodrug

Belonging to the field of organic chemistry and pharmaceutical chemicals, the invention discloses preparation and application of a monodisperse polyethylene glycol monomethyl ether modified propofol prodrug with a novel structure. Monodisperse polyethylene glycol monomethyl ether and propofol can be connected by an in-vivo degradable chemical bond to prepare a series of carbonic ester type and acetic ester type prodrugs respectively. By adjusting the length of the monodisperse polyethylene glycol monomethyl ether chain, the method can synthesize corresponding water-soluble propofol prodrugs, the longer the monodisperse polyethylene glycol monomethyl ether chain is, the better the water solubility is, along with the improvement of the water solubility, the prodrug can be made into aqueous solution preparations so as to avoid the defects of fat emulsion in propofol fat emulsions. The method provided by the invention has the advantages of simple reaction, mild conditions and low cost, andis convenient for industrial production.

Ceria supported gold-platinum catalysts for the selective oxidation of alkyl ethoxylates

This work covers the development of a ceria based AuPt catalyst for the selective aerobic oxidation of alkyl ethoxylates to their corresponding carboxylic acids. By optimizing metal loading and the Au to Pt ratio the activity of the catalyst could be increased significantly, while maintaining total selectivity. Although the choice of ceria as a support helped to suppress intermediate metal leaching, the catalyst still showed poor long-term stability in repeated batches. The cause for deactivation could finally be identified by TPR studies as over-oxidation. These suspicions were confirmed by a long-term stability study in continuous-mode. It proved to be possible to deactivate the catalyst on purpose by employing unfavourable oxidising reaction conditions, i.e. low substrate concentrations and excess oxygen. By avoiding such unfavourable conditions either in continuous-flow mode or in repeated batches, the long-term stability of the catalyst increased tremendously. A substrate screening of various ethoxylates showed that the catalyst was very well-suited to selectively oxidize a wide range of alkyl ethoxylates.

1-(2H)-ISOQUINOLONE DERIVATIVE

The present invention provides a compound having high antitumor activity, which is useful for therapeutic and preventive agents effective for proliferative diseases such as cancer; a production method thereof; an intermediate compound useful for such production; and a pharmaceutical composition comprising such a compound. The present invention provides a compound represented by the formula (1): wherein X represents an aryl group or heteroaryl group which may be substituted, Cy represents a 4- to 7-membered monocyclic heterocyclic ring or a 8- to 10-membered condensed heterocyclic ring which may be substituted, and Z represents O, S, or NRa; or a prodrug thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutical and a pharmaceutical composition which comprise the compound.